AIDS and Cancer Specimen Resource (ACSR) (UM1)
Post Date
December 12th 2012
Application Due Date
February 14th 2013
Funding Opportunity Number
RFA-CA-13-005
CFDA Number(s)
93.393
93.394
93.395
93.396
93.399
Funding Instrument Type(s)
Cooperative Agreement
Funding Activity Categories
Number of Awards
1
Eligibility Categories
State Governments
County Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Funding
-
Estimated Total Funding:
$3900000
-
Award Range:
$None - $None
Grant Description
In this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is seeking applications for the AIDS and Cancer Specimen Resource (ACSR). The primary objective of the ACSR will be to acquire, store and equitably distribute tumor tissues, biological fluids and associated demographic data from patients with HIV-associated malignancies. In addition, the ACSR will serve and support biorepository banking activities for the AIDS Malignancy Clinical Trials Consortium (AMC). The AMC is an NCI funded, multicenter clinical trials group that performs clinical trials research in the treatment and prevention of HIV-associated malignancies. Due to the changing HIV epidemic and recent estimates of the associated malignancy trends, applicants are encouraged to focus their efforts in acquiring high priority collections that would include: 1) biospecimens with associated clinical, pathological, diagnostic, and demographic data; 2) fresh frozen biospecimens that are suitable for comprehensive molecular and genomic analyses; 3) biospecimens collected with informed consent acceptable for high level future use for deep sequencing and genome wide association studies; 4) biospecimens representing non-AIDS defining cancers (NADCs); and 5) biospecimens from the developing world, especially Sub-Saharan Africa.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
-
More Information:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-13-005.html
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: